KLOW - GHK-Cu (50mg) / KPV (10mg) / BPC-157 (10mg) / TB500 (10mg)
The Science
Overview
KLOW extends the GLOW family by adding KPV (lysine-proline-valine, the C-terminal tripeptide of α-MSH) to a copper-peptide tissue-repair base. KPV is studied for its anti-inflammatory and antimicrobial activity, particularly in mucosal and skin-research models.
The four-peptide blend layers matrix remodeling (GHK-Cu), cytoprotective repair (BPC-157), angiogenesis (TB500), and inflammation modulation (KPV) into a single research formulation.
Laboratory Observations
Research-Observed Areas of Interest
Four-Mechanism Coverage
Combines anti-inflammatory, matrix-remodeling, cytoprotective, and angiogenic peptides in a single standardized research blend.
Inflammation-Focused Repair Research
KPV component extends the GLOW backbone into models where inflammatory signaling is a primary endpoint.
Mucosal and Skin Studies
KPV's documented activity in mucosal-barrier and skin-inflammation research makes KLOW relevant to integrated repair models.
Pre-Standardized Ratios
Eliminates per-experiment compounding variance across four active peptides.
Mechanism of Action
Mechanism of Action
Anti-Inflammatory Tripeptide Signaling
KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine output (IL-1β, IL-6, TNF-α) in skin and mucosal research models — distinct from the matrix and repair pathways of the companion peptides.
Copper-Peptide Matrix Remodeling
GHK-Cu drives collagen synthesis and cross-linking via copper-dependent enzymes including lysyl oxidase.
Cytoprotective Repair
BPC-157 modulates VEGF and growth-factor expression supporting connective-tissue and barrier integrity in laboratory models.
Angiogenic Support
TB500 supports endothelial migration and microvascular sprouting in wound-healing research.
FAQ
Frequently Asked Questions
What is KPV?+
Lysine-proline-valine, the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). It is studied for anti-inflammatory and antimicrobial activity, particularly in mucosal and skin research.
Why combine KPV with copper-peptide and repair peptides?+
Research interest centers on whether layered inflammation control (KPV) plus matrix remodeling (GHK-Cu) plus cytoprotective and angiogenic signaling (BPC-157, TB500) produces synergistic effects in integrated repair models.
Research-Only Notice
KLOW - GHK-Cu (50mg) / KPV (10mg) / BPC-157 (10mg) / TB500 (10mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.